These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 12435293)

  • 21. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
    Nabholtz JM; North S; Smylie M; Mackey J; Au HJ; Au R; Morrish D; Salter E; Tonkin K
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of taxanes in the treatment of breast cancer.
    Capri G; Tarenzi E; Fulfaro F; Gianni L
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
    Hudis C
    Clin Breast Cancer; 2002 Dec; 3(5):326-32. PubMed ID: 12533262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Docetaxel in the adjuvant treatment of operable breast carcinoma. News from ASCO 2002].
    Montemurro F
    Tumori; 2002; 88(4):A1-7. PubMed ID: 12402832
    [No Abstract]   [Full Text] [Related]  

  • 25. [Breast cancer: HER2 changes one's cards on the table].
    Lopez M
    Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docetaxel-anthracycline combinations in metastatic breast cancer.
    Nabholtz JM
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S3-9. PubMed ID: 12868800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing adjuvant chemotherapy in early-stage breast cancer.
    Perez E; Muss HB
    Oncology (Williston Park); 2005 Dec; 19(14):1759-67; discussion 1768, 1772-4, 1777-8. PubMed ID: 16506631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and use of epirubicin-based therapy in the adjuvant setting.
    Mouridsen HT
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S34-40. PubMed ID: 11970748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of taxanes in the treatment of breast cancer.
    Nabholtz JM; Gligorov J
    Expert Opin Pharmacother; 2005 Jun; 6(7):1073-94. PubMed ID: 15957963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the use of taxanes in the adjuvant therapy of breast cancer.
    Nabholtz JM; Vannetzel JM; Llory JF; Bouffette P
    Clin Breast Cancer; 2003 Aug; 4(3):187-92. PubMed ID: 14499011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
    Valero V; Perez E; Dieras V
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):15-23. PubMed ID: 11552226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
    Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospects with docetaxel in the treatment of patients with breast cancer.
    Marty M; Extra JM; Cottu PH; Espié M
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S26-9. PubMed ID: 9486101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
    Jackisch C; von Minckwitz G; Eidtmann H; Costa SD; Raab G; Blohmer JU; Schütte M; Gerber B; Merkle E; Gademann G; Lampe D; Hilfrich J; Tulusan AH; Caputo A; Kaufmann M
    Clin Breast Cancer; 2002 Oct; 3(4):276-80. PubMed ID: 12425756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expanding options in breast cancer.
    Crown JP
    Anticancer Drugs; 1999 Nov; 10 Suppl 1():S19-24. PubMed ID: 10630364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].
    Galligioni E
    Tumori; 2001; 87(1 Suppl 2):S1-9. PubMed ID: 11357871
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.